Compound 49b significantly increased ALX/FPR2 levels, with no influence on RvD1 or GPR32 levels.

<p>RvD1 (A), ALX/FPR2 (B) and GPR32 (C) expression in PMN exposed to normal glucose (NG), normal glucose+Compound 49b (NG+49b), high glucose (HG) or high glucose treated with Compound 49b (HG+49b). *P<0.05 vs. NG, ^#P<0.05 vs. HG. N = 4 for each treatment.